Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03629756 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Arcus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 15
- Study locations
NCT03629756 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that has completed, run by Arcus Biosciences. The registered enrollment target is 48 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT03629756, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, has completed, sponsored by Arcus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with zimberelimab (AB122) (an anti-PD-1 antibody) in participants with advanced malignancies.
Conditions Studied
Interventions
- DRUG Zimberelimab
- DRUG Etrumadenant
Study Locations (15)
Texas
- Texas Oncology, P.A. - Fort Worth Cancer Center - Fort Worth
- Texas Oncology, P.A. - San Antonio Medical Center - San Antonio
- Texas Oncology, P.A. - Tyler - Tyler
California
- University of California, Los Angeles - Los Angeles
- The Angeles Clinic and Research Institute - Los Angeles
Michigan
- University of Michigan - Ann Arbor
- QUEST Research Institute - Royal Oak
Arizona
- Scottsdale Healthcare Hospitals dba HonorHealth - Scottsdale
Colorado
- Rocky Mountain Cancer Centers (Midtown) - Denver
North Carolina
- Carolina BioOncology Institute - Huntersville
South Carolina
- Prisma Health - Greenville
Washington
- Medical Oncology Associates dba Summit Cancer Centers - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2018-07-24 |
| Est. Completion | 2021-09-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03629756
The ClinicalTrials.gov registry entry for NCT03629756 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Zimberelimab is the first listed.
NCT03629756 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Texas, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT03629756 about?
NCT03629756 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies". This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with zimberelimab (AB122) (an anti-PD-1 antibody) in participants with advanced malign...
What is the current status of trial NCT03629756?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2018-07-24. Estimated completion is 2021-09-03.
What conditions does trial NCT03629756 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Ovarian Cancer, Melanoma.
What interventions are being tested in trial NCT03629756?
The interventions under investigation include: Zimberelimab (DRUG), Etrumadenant (DRUG).
Who is sponsoring clinical trial NCT03629756?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03629756 being conducted?
This trial has 15 study locations across Arizona, California, Colorado, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.